How Much CJC-1295 No DAC Per Day? (Dosing Protocol)
CJC-1295 no DAC isn't dosed once daily like its DAC counterpart. That's the single most common protocol error. Without the drug affinity complex extending half-life, the modified peptide clears rapidly, making multiple daily injections the standard approach for maintaining stable growth hormone-releasing hormone (GHRH) receptor activation. Research from the Journal of Clinical Endocrinology & Metabolism examining GHRH analogues found that pulsatile administration. Mimicking natural GH secretion patterns. Produced superior anabolic outcomes compared to sustained elevation, which is why the no-DAC variant exists at all.
We've worked with researchers running CJC-1295 no DAC protocols for years. The gap between effective dosing and ineffective dosing comes down to three variables most reference guides never mention: injection frequency relative to half-life, timing around endogenous GH pulse windows, and the peptide's interaction with GHRP co-administration.
How much CJC-1295 no DAC should be injected per day?
Standard research protocols use 100–200mcg of CJC-1295 no DAC per injection, administered 1–3 times daily depending on study design. Total daily doses range from 100mcg (single daily injection) to 600mcg (200mcg administered three times daily). The peptide's half-life of approximately 30 minutes necessitates frequent dosing to maintain GHRH receptor occupancy, unlike the DAC version which achieves multi-day plasma stability. Injection timing is typically aligned with natural GH pulse windows. Pre-workout, before sleep, and optionally upon waking.
The most common mistake isn't miscalculating the dose. It's treating CJC-1295 no DAC like a once-daily medication when its pharmacokinetics demand pulsatile administration. The peptide's rapid clearance is a feature, not a flaw: it allows researchers to control GH secretion windows precisely rather than creating sustained elevation that downregulates pituitary responsiveness. This article covers the dose-response relationship between injection frequency and GH pulse amplitude, how to structure multi-injection protocols without receptor desensitisation, and what preparation errors negate the peptide's bioactivity entirely.
CJC-1295 No DAC: Mechanism and Half-Life
CJC-1295 without DAC (drug affinity complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the native hormone with four amino acid substitutions that improve stability. These modifications. Specifically glutamine-to-alanine at position 2, alanine-to-glutamine at position 8, alanine-to-leucine at position 15, and arginine-to-glutamine at position 20. Extend enzymatic resistance from under one minute (native GHRH) to approximately 30 minutes in plasma. This is still a short half-life by peptide standards, which is why the compound requires multiple daily administrations to sustain GHRH receptor activation.
The peptide works by binding to GHRH receptors on somatotroph cells in the anterior pituitary, triggering intracellular cAMP accumulation that drives GH synthesis and secretion. Unlike synthetic GH, which provides exogenous hormone and suppresses endogenous production, CJC-1295 no DAC amplifies the body's own pulsatile GH release. Preserving hypothalamic-pituitary feedback loops. Research published in Growth Hormone & IGF Research demonstrated that GHRH analogue administration produced GH pulses with 2–4× the amplitude of baseline secretion without altering pulse frequency, meaning the pituitary retains physiological control over timing.
The absence of the DAC modification is deliberate. The DAC variant. A reactive chemical group that binds to endogenous serum albumin. Extends half-life to approximately 6–8 days, allowing weekly dosing. The no-DAC version clears within hours, which initially seems like a disadvantage but provides precise control over GH secretion timing. Researchers use the no-DAC form when they want to align injections with specific physiological windows (pre-sleep for nocturnal GH peaks, pre-workout for anabolic signalling) or when co-administering with GHRP peptides that require synergistic pulsatile dosing.
Dosing Protocols: Single vs Multiple Daily Injections
Most research protocols fall into one of three categories: single daily injection (100–200mcg before sleep), twice-daily injection (100–200mcg pre-workout and pre-sleep), or three-times-daily injection (100–200mcg upon waking, pre-workout, and pre-sleep). The total daily dose ranges from 100mcg at the conservative end to 600mcg at the upper research boundary, but dose escalation doesn't scale linearly with GH output. Frequency matters more than total quantity.
Single daily dosing at 100–200mcg is the minimalist approach, typically timed 30–60 minutes before sleep to coincide with the nocturnal GH pulse window. The body naturally releases the largest GH pulse of the day during slow-wave sleep (stages 3–4), and pre-sleep GHRH administration amplifies this endogenous surge. A study in The Journal of Clinical Investigation found that pre-sleep GHRH analogue injection increased nocturnal GH secretion by 3.2-fold compared to placebo without affecting daytime GH patterns. This protocol works well for researchers prioritising recovery and lipolysis over acute anabolic signalling.
Twice-daily protocols split the dose into two 100–200mcg injections: one pre-workout (60–90 minutes before training) and one pre-sleep. This approach captures both the exercise-induced GH pulse and the nocturnal pulse, extending the anabolic window across the day. Pre-workout GH elevation enhances lipolysis during training and increases post-exercise IGF-1 synthesis in skeletal muscle. Research from the European Journal of Applied Physiology showed that GHRH administration 90 minutes before resistance training increased post-workout serum IGF-1 by 28% compared to training alone, suggesting enhanced anabolic signalling in muscle tissue.
Three-times-daily protocols. Typically 100–200mcg upon waking, pre-workout, and pre-sleep. Represent the upper range of research dosing. Morning administration targets the smaller post-awakening GH pulse, midday or pre-workout dosing aligns with training windows, and evening dosing amplifies nocturnal secretion. Total daily doses in this range (300–600mcg) approach the threshold where receptor desensitisation becomes a concern: continuously elevated GHRH receptor occupancy can downregulate receptor density over weeks, blunting GH response. This is why we recommend cycling protocols rather than continuous administration beyond 12–16 weeks.
CJC-1295 No DAC: Full Dosing Comparison
Single Daily
100–200mcg
1
Recovery-focused protocols prioritising sleep-phase GH
Pre-sleep (nocturnal pulse amplification)
Best for minimalist protocols. Captures the largest endogenous pulse without multiple injections
Twice Daily
2
200–400mcg
Balanced anabolic and lipolytic signalling
Pre-workout + pre-sleep
Most common research protocol. Extends GH elevation across waking and sleeping phases
Three Times Daily
3
300–600mcg
Maximal GH output for body composition studies
Morning + pre-workout + pre-sleep
Upper research boundary. Higher receptor occupancy increases desensitisation risk after 12+ weeks
GHRP Co-Administration
100mcg CJC + 100–200mcg GHRP-2/6
2–3
200–600mcg combined
Synergistic GH release via dual pathway activation
Timed together at each injection
Produces 5–10× baseline GH peaks when dosed simultaneously. Standard for advanced protocols
What If: CJC-1295 No DAC Scenarios
What If I Miss a Scheduled Injection?
Skip the missed dose and continue with your next scheduled injection at the planned time. Do not double-dose to 'catch up'. GHRH receptor saturation doesn't scale proportionally with dose, and excessively large single injections increase the risk of side effects (flushing, headache, transient hypoglycaemia) without meaningfully increasing GH output. Missing a single injection in a multi-dose protocol reduces that day's total GH elevation but doesn't compromise long-term outcomes. Missing multiple consecutive doses over 48–72 hours may require restarting at a lower dose to re-establish tolerance if initial injections caused side effects during titration.
What If I Experience Flushing or Headache After Injection?
Flushing and mild headache are vasodilatory effects mediated by nitric oxide release downstream of GHRH receptor activation. They're physiological responses, not allergic reactions. These effects typically resolve within 20–40 minutes and diminish with repeated dosing as the body adapts. If symptoms are severe or persistent, reduce the dose by 25–50% for one week before re-escalating. Injecting on an empty stomach can intensify vasodilatory effects; administering the peptide 30–60 minutes after a small meal containing healthy fats often reduces symptom severity.
What If I Want to Combine CJC-1295 No DAC with a GHRP?
Combining CJC-1295 no DAC with a growth hormone-releasing peptide (GHRP-2, GHRP-6, ipamorelin, or hexarelin) is standard practice in advanced research protocols. GHRH analogues and GHRPs act on different receptors. GHRH receptors on somatotrophs and ghrelin receptors on the same cells. Creating synergistic GH release. Research from Endocrinology found that co-administration of GHRH + GHRP-6 produced GH peaks 5–10× higher than either peptide alone, with the combination outperforming the sum of individual responses. Standard dosing: 100mcg CJC-1295 no DAC + 100–200mcg GHRP administered simultaneously, 2–3 times daily. Both peptides must be injected within the same 5-minute window to capture peak synergy.
The Blunt Truth About CJC-1295 No DAC Dosing
Here's the honest answer: more isn't better beyond 200mcg per injection. The GHRH receptor saturates at relatively low peptide concentrations, meaning doses above 200mcg per injection don't produce proportionally higher GH output. They just increase side effect probability and waste expensive peptide. Research protocols demonstrating meaningful IGF-1 elevation and body composition changes consistently used 100–200mcg per injection, not 500mcg megadoses. The dose-response curve flattens sharply above this range.
The second truth: injection frequency drives efficacy more than total daily dose. A researcher injecting 100mcg three times daily (300mcg total) will see better outcomes than someone injecting 300mcg once daily, even though the total quantity is identical. The no-DAC variant's short half-life means plasma levels fall to baseline within 2–3 hours post-injection. Spreading doses across the day maintains receptor activation, while a single large dose creates a brief spike followed by prolonged inactivity.
Reconstitution and Storage Protocols
CJC-1295 no DAC is supplied as lyophilised (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Standard reconstitution uses 2mL bacteriostatic water added to a 2mg vial, yielding a 1mg/mL (1000mcg/mL) concentration. Each 0.1mL (10 units on an insulin syringe) contains 100mcg of peptide. Add the bacteriostatic water slowly down the side of the vial, allowing it to dissolve naturally without shaking or vigorous agitation. Shaking denatures the peptide structure, reducing bioactivity.
Unreconstituted lyophilised powder should be stored at −20°C (standard freezer temperature). Once reconstituted, the peptide must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation. A vial left at room temperature for 6–8 hours loses potency even if it's subsequently refrigerated. This is why traveling with reconstituted peptides requires a purpose-built insulin cooler that maintains 2–8°C for 36–48 hours without external power.
The biggest reconstitution mistake isn't contamination. It's injecting air into the vial while drawing solution. Standard practice is to inject 0.1mL of air into the vial before drawing 0.1mL of solution to equalise pressure, but this creates positive pressure that forces peptide solution back through the needle on subsequent draws, contaminating the needle tip with air exposure. Better protocol: draw solution without injecting air, accepting the slight vacuum that forms. The vacuum prevents backflow contamination and extends the vial's sterile usable life.
Key Takeaways
CJC-1295 no DAC requires 1–3 daily injections at 100–200mcg per dose due to its 30-minute half-life, unlike the DAC version which allows weekly dosing.
Injection frequency drives efficacy more than total daily dose. 100mcg administered three times daily outperforms 300mcg administered once.
Standard protocols range from single daily pre-sleep injection (100–200mcg) to three-times-daily dosing (300–600mcg total), with twice-daily being most common.
Co-administration with GHRP peptides produces synergistic GH release 5–10× higher than either compound alone when injected simultaneously.
Reconstituted peptide must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible denaturation.
Doses above 200mcg per injection don't produce proportionally higher GH output due to GHRH receptor saturation.
If you're structuring a research protocol and need high-purity peptides with verified amino-acid sequencing, explore our CJC1295 Ipamorelin 5MG 5MG blend or browse our full peptide collection for other GHRH and GHRP compounds. Every batch is small-batch synthesised with exact sequencing. No fillers, no approximations, just the molecule you ordered at the purity your research demands.
Frequently Asked Questions
Standard research dosing ranges from 100–200mcg per injection, administered 1–3 times daily depending on protocol design. Total daily doses typically fall between 100mcg (single daily injection) and 600mcg (200mcg three times daily). The peptide’s 30-minute half-life requires multiple daily administrations to maintain GHRH receptor activation, unlike the DAC version which achieves multi-day plasma stability.
Yes, single daily dosing at 100–200mcg before sleep is a valid minimalist protocol that targets the nocturnal GH pulse window. However, this approach limits GH elevation to one phase of the day — twice or three-times-daily dosing extends GHRH receptor activation across multiple endogenous pulse windows, producing superior outcomes in most body composition and anabolic signalling studies.
CJC-1295 with DAC contains a drug affinity complex that binds to serum albumin, extending half-life to 6–8 days and allowing weekly or twice-weekly dosing. CJC-1295 without DAC has a 30-minute half-life and requires daily or multiple-daily injections. The no-DAC version provides precise control over GH pulse timing but demands higher injection frequency to maintain therapeutic effect.
CJC-1295 no DAC is typically 20–40% less expensive per milligram than the DAC variant because the synthesis process is simpler (no albumin-binding modification required). However, total protocol cost depends on injection frequency — researchers using the no-DAC version three times daily consume more peptide per week than those using the DAC version once weekly, potentially offsetting the per-milligram savings.
Common side effects include transient flushing, mild headache, and injection-site irritation — all mediated by vasodilatory nitric oxide release downstream of GHRH receptor activation. These effects typically resolve within 20–40 minutes and diminish with repeated dosing. Rare adverse events include transient hypoglycaemia and water retention. Doses above 200mcg per injection increase side effect probability without proportional efficacy gains.
Co-administration with growth hormone-releasing peptides (GHRP-2, GHRP-6, ipamorelin, hexarelin) is standard in advanced research protocols. GHRH analogues and GHRPs act on different receptors, creating synergistic GH release 5–10× higher than either peptide alone. Standard dosing: 100mcg CJC-1295 no DAC + 100–200mcg GHRP injected simultaneously, 2–3 times daily.
Unreconstituted lyophilised powder should be stored at −20°C. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that neither appearance nor potency testing at home can detect — a vial left at room temperature for 6–8 hours loses bioactivity even if subsequently refrigerated.
Doses above 200mcg per injection don’t produce proportionally higher GH output because the GHRH receptor saturates at relatively low peptide concentrations. The dose-response curve flattens sharply above this range — excess peptide is metabolised without binding to additional receptors. Higher doses increase side effect probability (flushing, headache) and waste expensive peptide without meaningful efficacy gains.
Yes, but temperature control is critical. Reconstituted peptide must remain between 2–8°C during transport — use a purpose-built insulin cooler that maintains this range for 36–48 hours without external power. Unreconstituted lyophilised powder tolerates short-term ambient temperature (up to 25°C for 24–48 hours), making it more travel-friendly if you can reconstitute on-site.
With a 30-minute half-life, plasma concentrations fall to negligible levels within 2–3 hours post-injection. Complete metabolic clearance occurs within 24 hours. This rapid clearance allows researchers to discontinue protocols without extended washout periods and enables precise timing around specific experimental windows without residual GHRH receptor activation.